Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050895 · ClinicalTrials.gov registry record · Phase 3
Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 775
- Enrollment target
NCT00050895 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 775 participants.
The verdict
NCT00050895, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 775 participants
- Enrollment target
Study Summary
With new strategies and drugs available, many different regimens exist for the treatment of HIV. The purpose of this study is to compare three different anti-HIV drug regimens as first-time treatments for HIV infection.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Efavirenz
- DRUG Stavudine
- DRUG Lopinavir/ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 775 participants |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050895
The ClinicalTrials.gov registry entry for NCT00050895 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 775 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Zidovudine is the first listed.
NCT00050895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050895 about?
NCT00050895 is a clinical study titled "Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients". With new strategies and drugs available, many different regimens exist for the treatment of HIV. The purpose of this study is to compare three different anti-HIV drug regimens as first-time treatments for HIV infection.
What is the current status of trial NCT00050895?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 775 participants. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00050895?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Efavirenz (DRUG), Stavudine (DRUG), Lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00050895?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.